High Effectiveness of Tildrakizumab Over 52 Weeks in Patients With or Without Nail Psoriasis: Results From the Phase IV POSITIVE Austrian Subset

The study assessed the effectiveness of tildrakizumab in 68 Austrian patients with moderate-to-severe plaque psoriasis, including 42 with nail psoriasis, over 52 weeks. Results showed significant improvement in symptoms and well-being, with mean PASI scores decreasing from 11.0 to 0.8 and mean NAPSI scores in nail patients decreasing from 44.4 to 15.7. Additionally, the WHO-5 well-being index increased from 50.2 to 65.7. By week 52, 96.5% of patients achieved a PASI ≤3, and 71.9% achieved a PASI ≤1. The study concluded that tildrakizumab significantly improved patient outcomes in a real-world setting, regardless of baseline PASI and nail psoriasis status.